Today's signal
Isomorphic Labs, the AI drug design spinout from Google DeepMind led by Nobel laureate Demis Hassabis, closed a $2.1 billion Series B on May 12. The round is led by Thrive Capital and includes Alphabet, Temasek, and the UK Sovereign AI Fund. Total capital raised now stands at roughly $2.6 billion.
Why it matters
Isomorphic's platform, IsoDDE, is built on the AlphaFold lineage and is designed to go from protein structure prediction all the way to identifying viable drug candidates across multiple disease areas. The company already has R&D partnerships with Eli Lilly, Novartis, and Johnson and Johnson, which together represent billions in potential milestone payments. The $2.1 billion will go toward scaling the platform, pushing drugs closer to clinical trials, and aggressive hiring across AI research and drug design. This is the largest private funding round in AI drug discovery history.
Here is what the press release buries: Hassabis originally promised a human clinical trial by end of 2025. That date came and went. The revised target is end of 2026. As of today, no Isomorphic-designed compound has been administered to a human patient.
The take
$2.6 billion raised and not a single patient dosed yet. The investor conviction here is real, and the science is credible. But the framing around "solving all disease" is doing a lot of work. The first clinical trial will either validate five years of bold claims or force a serious recalibration. Right now this is the biggest bet in AI biotech, backed by some of the world's most sophisticated capital, still waiting for its first real test.
The number
$1.7 billion. That is the maximum milestone value attached to Isomorphic's partnership deal with Eli Lilly alone, on top of a $45 million upfront payment signed in January 2024. Novartis and Johnson and Johnson added further billions in potential value. The pharma industry is not hedging here. It is placing serious money on a platform that has yet to put a drug in a human body.
Read the full breakdown at: analyticsdrift.com/isomorphic-labs-raises-2-billion-ai-drug-discovery